Read our latest updates & insights

Amgen submits BLA for biosimilar rituximab to FDA. 

Amgen and Tanvex file a joint stipulation of dismissal in their filgrastim dispute. The stipulation of dismissal states that parties will bear their own costs and attorney’s fees.

NeuClone announces completion of patient recruitment and dosing in Ph I trials of ustekinumab biosimilar.

Qilu receives Chinese approval for its bevacizumab biosimilar, Ankada®. 

Dong-A Socio Holdings and Meiji Seika announce commencement of Ph I trials of ustekinumab biosimilar.

Lupin releases results of Ph III trials of etanercept biosimilar, reporting similarity with the reference product.

Pfizer receives positive CHMP opinion for its biosimilar adalimumab product.

Boehringer Ingelheim has released the results of its Ph III trials of its biosimilar adalimumab, announcing the product demonstrated non-inferior efficacy and similar safety profile to the originator.

A new study released by the Universities of Saskatchewan and Alberta reveal substantial savings for health services switching to Apotex’s Grastofil®. The study analysed Canadian sales between 2016 and 2018, finding that the biosimilar accounted for $13,443,873 in savi...

AffaMed receives Chinese approval to commence Ph III trials of Samsung’s trastuzumab biosimilar SB3.